ModerateCardiovascularHeart failure with reduced ejection fractionuk-plab-1
A 68-year-old man with known HFrEF (left ventricular ejection fraction 30%) is reviewed in clinic. He is currently on Ramipril and Furosemide and remains breathless on minimal exertion (NYHA class III). His blood pressure is 118/70 mmHg and renal function is stable. According to current guidance, which additional class of drug should be optimised as a disease-modifying therapy?